Streetbeat News

Analyst Ratings

BKNG

Benchmark analyst Daniel Kurnos maintains a Buy rating on Booking Holdings (NASDAQ:BKNG) but lowers the price target from $4700 to $4600.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 4:31 pm

TWST

Scorpion Capital has reiterated its short position on Twist Bioscience (TWST), expressing strong conviction that the stock is worthless. They plan to release detailed thoughts and possibly a follow-up report to their November 2022 short report.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 4:29 pm

CRSR

Goldman Sachs analyst Eric Sheridan maintains a Neutral rating on Corsair Gaming (NASDAQ:CRSR) but lowers the price target from $13 to $9.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 4:29 pm

KKR

Citigroup analyst Chris Allen maintains a Buy rating on KKR and raises the price target from $130 to $150.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 4:29 pm

CGNX

Goldman Sachs analyst Joe Ritchie maintains a Sell rating on Cognex (NASDAQ:CGNX) and lowers the price target from $45 to $39.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 4:28 pm

BV

Goldman Sachs analyst George Kelly maintains a Sell rating on BrightView Holdings (NYSE:BV) and raises the price target from $10 to $11.3.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 4:27 pm

W

Citigroup analyst Ygal Arounian maintains a Buy rating on Wayfair (NYSE:W) but lowers the price target from $85 to $70.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 4:26 pm

BFAM

Goldman Sachs analyst George Tong maintains a Buy rating on Bright Horizons Family (NYSE:BFAM) and raises the price target from $125 to $142.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 4:26 pm

APPN

Goldman Sachs analyst Kevin Kumar maintains a Buy rating on Appian (NASDAQ:APPN) but lowers the price target from $47 to $41.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 4:25 pm

NBIX

Citigroup analyst David Hoang maintains a Neutral rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $150 to $158.

Portfolio Pulse from Benzinga Newsdesk

August 02, 2024 | 4:25 pm